Description

Ibandronic Acid Concentrated Solution for Infusions 1 mg/ml. 6 ml. (6 mg.)

Ingredients

Active ingredient: Ibandronic acid. Inactive ingredients may include mannitol, sodium chloride, and water for injection.

Dosage

Dosage: The recommended dose is 6 mg administered as a 6 ml intravenous infusion over at least 15 minutes every 3-4 weeks.

Indications

Indications: This medication is indicated for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral fractures.

Contraindications

Contraindications: Do not use in patients with hypocalcemia. This medication is contraindicated in individuals with a known hypersensitivity to ibandronic acid.

Directions

Administration: Administer as a slow intravenous infusion over at least 15 minutes. Follow all instructions provided by healthcare professionals.

Scientific Evidence

Pharmacological Effects: Ibandronic acid belongs to the bisphosphonate class of drugs, which work by inhibiting bone resorption. By binding to hydroxyapatite crystals in bone, ibandronic acid suppresses osteoclast activity, leading to increased bone mineral density and reduced fracture risk.

Clinical Trials: Clinical studies have demonstrated the efficacy of ibandronic acid in reducing the incidence of vertebral fractures in postmenopausal women with osteoporosis. Research by Black et al. (2007) showed a significant decrease in the risk of new vertebral fractures with ibandronic acid treatment compared to placebo.

Additional Information

• Storage: Store the solution at controlled room temperature between 20-25°C (68-77°F).
• Monitoring: Regular monitoring of calcium levels is recommended during treatment with ibandronic acid.